IDEC and Caprion Pharmaceuticals to Search for Novel Cancer Antigen Targets
Business Review Editor
Abstract
IDEC Pharmaceuticals enlisted Caprion to collaborate on the discovery of novel antigen targets in the development of anticancer therapeutics using Caprion’s proprietary subcellular proteomics discovery platform CellCarta™.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.